N4 Pharma, a Derby-based biotech firm, has expanded its senior leadership team as it moves to accelerate the development and commercial readiness of its Nuvec® delivery technology.
The new team includes experienced figures from global pharmaceutical and biotech organisations, brought in to support internal R&D, commercial strategy, and manufacturing functions.
Dr Fiona McLaughlin will lead research and development, drawing on over two decades of oncology drug development at GSK, Bayer, and Avacta. Dr Mark Edbrooke, with prior leadership roles in functional genomics at GSK and oncology at AstraZeneca, takes up the role of head of strategy. Commercial director Dr Simon Bennett brings experience from more than 70 biopharma companies, having facilitated over 80 commercial transactions. Dr Margaret Courtney, now leading Chemistry, Manufacturing and Controls (CMC), has consulted widely across biotech and pharma on drug delivery and contract manufacturing operations.
The appointments reflect N4 Pharma’s focus on advancing its proprietary Nuvec nanoparticle platform, designed to enhance the delivery of RNA and DNA therapeutics. The company aims to secure commercial partnerships and establish an internal pipeline of RNA-based therapies.
